Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/16590
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | ALONSO ABAD, Ariel | - |
dc.contributor.author | VAN DER ELST, Wim | - |
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | BUYSE, Marc | - |
dc.date.accessioned | 2014-04-04T10:03:03Z | - |
dc.date.available | 2014-04-04T10:03:03Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | CLINICAL INVESTIGATION, 3 (12), p. 1147-1155 | - |
dc.identifier.issn | 2041-6792 | - |
dc.identifier.uri | http://hdl.handle.net/1942/16590 | - |
dc.description.abstract | Surrogate end point evaluation has received a lot of attention for approximately a quarter of a century. Throughout this time, the topic has been surrounded with both hopes and perils. The history of the evaluation of surrogate end point evaluation is described, from Prentice’s definition, via single-trial evaluation to meta-analytic approaches. While based on technical developments and advances in statistical methodology, the treatment of the topic here is largely nontechnical. A perspective is given as to what might be a sensible way forward. It is clear that statistical evaluation can offer a contribution to the discussion as to whether a surrogate will be adopted and in what form, but can never be seen as the sole decision maker. While there is room for the adoption of surrogates, it is very important that pitfalls and drawbacks be kept in mind at all times. | - |
dc.language.iso | en | - |
dc.rights | © 2013 Future Science Ltd. | - |
dc.subject.other | adjusted association; biomarker; causal inference; information theory; meta-analytic framework; proportion explained; surrogate end point; surrogate marker; surrogate threshold effect | - |
dc.title | Review: Clinical Trial Methodology: Surrogate endpoints: when should they be used? | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1155 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1147 | - |
dc.identifier.volume | 3 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.identifier.vabb | c:vabb:378901 | - |
dc.identifier.doi | 10.4155/CLI.13.105 | - |
item.fulltext | With Fulltext | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | ALONSO ABAD, Ariel | - |
item.contributor | VAN DER ELST, Wim | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | BUYSE, Marc | - |
item.fullcitation | MOLENBERGHS, Geert; ALONSO ABAD, Ariel; VAN DER ELST, Wim; BURZYKOWSKI, Tomasz & BUYSE, Marc (2013) Review: Clinical Trial Methodology: Surrogate endpoints: when should they be used?. In: CLINICAL INVESTIGATION, 3 (12), p. 1147-1155. | - |
item.accessRights | Restricted Access | - |
item.validation | vabb 2019 | - |
crisitem.journal.issn | 2041-6792 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Molenberghs Rev.pdf Restricted Access | Published version | 2.84 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.